Coloplast A/S (OTCMKTS:CLPBY) Shares Down 4.5% – Should You Sell?

Shares of Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) were down 4.5% during mid-day trading on Tuesday . The stock traded as low as $6.28 and last traded at $6.32. Approximately 13,134 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 582,739 shares. The stock had previously closed at $6.6170.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on CLPBY shares. Kepler Capital Markets upgraded shares of Coloplast A/S to a “strong-buy” rating in a research note on Wednesday, May 20th. The Goldman Sachs Group lowered shares of Coloplast A/S from a “hold” rating to a “strong sell” rating in a research note on Tuesday, April 7th. Finally, Sanford C. Bernstein upgraded shares of Coloplast A/S to a “hold” rating in a research note on Wednesday, January 28th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold”.

Coloplast A/S Stock Performance

The firm has a market cap of $14.06 billion, a price-to-earnings ratio of 44.57, a price-to-earnings-growth ratio of 1.99 and a beta of 0.15. The stock’s 50 day moving average is $6.56 and its 200 day moving average is $7.75. The company has a current ratio of 1.30, a quick ratio of 0.81 and a debt-to-equity ratio of 1.50.

Coloplast A/S (OTCMKTS:CLPBY) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.01. Coloplast A/S had a net margin of 7.46% and a return on equity of 31.96%. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.11 billion. Analysts anticipate that Coloplast A/S Sponsored ADR will post 0.4 earnings per share for the current year.

Coloplast A/S Company Profile

Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.